FIELD: medicine.
SUBSTANCE: aqueous composition is obtained from purified water, has pH of 5.5 to 7.5, osmolality of 200 to 400 mOsm/kg, conductivity of 17 to 22.5 mS/cm at 25 °C and is prepared using filtered sea water in an amount of 1–20 %, potassium salts at a concentration of 90–180 mmol/l and Zn(X)2 in a concentration of 200–300 mcmol/l.
EFFECT: marine solution for applications on eyes, skin and mucous membranes is disclosed.
11 cl, 5 tbl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| OPHTHALMIC COMPOSITIONS CONTAINING MUCOADHESIVE POLYSACCHARIDES ABLE TO PROMOTE CORNEAL RE-EPITHELISATION | 2013 |
|
RU2663449C2 |
| OPHTHALMIC COMPOSITIONS CONTAINING MUCOADHESIVE POLYSACCHARIDES STIMULATING CORNEAL EPITHELIUM RECOVERY | 2006 |
|
RU2493854C2 |
| COMPOSITIONS AND METHODS FOR JAK PATH INHIBITION | 2010 |
|
RU2557982C2 |
| 1-ETHANOLAMIDE PGF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 2001 |
|
RU2252212C2 |
| AMIDE COMPOUNDS | 2015 |
|
RU2684906C2 |
| SUBSTITUTED DERIVATIVES OF N-[2-(4-PHENOXYPIPERIDINE-1-YL)-2-(1,3-THIAZOLE-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDINE-1-YL)-2-(1,3-THIAZOLE-5-YL)ETHYL]BENZAMIDE AS P2X7 RECEPTOR ANTAGONISTS | 2017 |
|
RU2755705C2 |
| COMPOSITION AND METHOD FOR TREATMENT OF EYE DISEASE ASSICIATED WITH NUCLEIC ACIDS | 2012 |
|
RU2642609C2 |
| iRNA-MEDIATED INHIBITION OF TUMOUR NECROSIS FACTOR-( RELATED CONDITIONS | 2007 |
|
RU2469090C2 |
| METHODS FOR TREATMENT USING JAK INHIBITOR COMPOUND | 2018 |
|
RU2764979C2 |
| COMPOSITION FOR TREATING CONTACT LENSES | 1998 |
|
RU2139094C1 |
